Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.59 USD

87.59
5,119,705

-1.18 (-1.33%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $87.59 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

HSIC Stock Likely to Get a Boost From New Henry Schein One Launches

by Zacks Equity Research

Henry Schein's dental software arm unveils Dentrix Eligibility offerings to elevate the insurance verification process.

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

VEEV Stock Up Following the Release of New Features of Veeva Site Connect

by Zacks Equity Research

Veeva Systems' Site Connect is likely to aid the sponsors in reducing trial time and expense.

CRL Stock May Benefit From New Neuroscience Research Collaboration

by Zacks Equity Research

Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.

Will Paragon 28 Stock Gain From the Latest Product Launch of R3FLEX?

by Zacks Equity Research

FNA recently introduced the R3FLEX Stabilization System, whose design should allow surgeons to restore a patient's soft tissue to a more natural anatomy.

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

by Zacks Equity Research

Veracyte looks poised to deliver robust performance owing to its progress with key drivers and the strength in its diagnostics tests.

Align Technology Stock Dips on Macroeconomic Issues, FX Headwind

by Zacks Equity Research

ALGN is facing a decline in Invisalign ASPs for comprehensive treatment options. This is resulting in a decline in the company's revenues.

COO Stock Up 0.4% Following the Launch of New Inserter for Paragard IUD

by Zacks Equity Research

Cooper Companies' latest launch is likely to simplify the insertion process of Paragard IUD, thus making it a more accessible contraceptive choice.

Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year?

by Zacks Equity Research

Here is how Addex Therapeutics Ltd. Sponsored ADR (ADXN) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Abbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?

by Zacks Equity Research

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.

Reasons to Retain Revvity Stock in Your Portfolio for Now

by Zacks Equity Research

RVTY's strong product portfolio raises optimism about the stock.

Boston Scientific (BSX) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Boston Scientific (BSX) closed at $81.37, marking a -0.72% move from the previous day.

QIAGEN Stock Likely to Gain on Collaboration for APOE Genotyping

by Zacks Equity Research

QGEN collaborates with Eli Lilly to develop a QIAstat-Dx IVD panel for APOE genotyping.

Should You Continue to Retain ABT Stock in Your Portfolio Now?

by Zacks Equity Research

Abbott's robust strength in Core Diagnostics and EPD businesses should continue to benefit in the upcoming quarters.

Butterfly Network's Stock Surges on iQ3 Device Launch in Europe

by Zacks Equity Research

Shares of BFLY gain almost 27% following the announcement of the launch of its latest handheld ultrasound device, Butterfly iQ3, in Europe.

New Partnerships to Aid Myriad Genetics Stock Amid Macro Issues

by Zacks Equity Research

MYGN focuses on effective capital deployment in key areas, including new tech-enabled tools and capabilities, innovation and commercial capabilities.

Reasons to Retain STERIS Stock in Your Portfolio for Now

by Zacks Equity Research

STE's strong prospects in the healthcare business arm bode well for investors.

Zynex Stock Rises on FDA Clearance of Its New Pain Management Device

by Zacks Equity Research

ZYXI recently received the Food and Drug Administration clearance for its new TensWave device. TensWave is designed to provide a comprehensive pain management solution.

Reasons to Retain Cardinal Health Stock in Your Portfolio Now

by Zacks Equity Research

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Embecta Stock Gains on FDA Clearance for Type 2 Diabetes Insulin Pump

by Zacks Equity Research

EMBC's shares close higher following FDA clearance for its disposable patch pump for insulin delivery, expanding the target market with its availability for type 2 diabetes.

Should You Consider Retaining ZBH Stock in Your Portfolio Now?

by Zacks Equity Research

Zimmer Biomet's robust efforts to expand the Knee business and a gradually stabilizing musculoskeletal market appear promising.

Should You Continue to Retain PODD Stock in Your Portfolio Now?

by Zacks Equity Research

Insulet's Omnipod 5 is set to drive growth in the upcoming quarters. Meanwhile, the stock is facing challenges due to economic uncertainties.

Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now

by Zacks Equity Research

QDEL's strong product portfolio raises optimism about the stock.

Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock

by Zacks Equity Research

Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.

Reasons to Hold Tandem Diabetes Stock in Your Portfolio Now

by Zacks Equity Research

Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.